Rhythm Pharmaceuticals announced three late-breaking abstracts accepted for presentation at ENDO 2025, highlighting new research on acquired hypothalamic obesity treatments. Rhythm Pharmaceuticals, a ...

TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and ...

BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals (RYTM), Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster ...

LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking presentations showcasing the results of a Phase 2b dose finding trial evaluating the efficacy and safety of ...

Abstract Title: A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks Click to enlarge “We are pleased that the ACR has recognized the importance of this ...

DENVER--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, ...

CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical-stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) to revolutionize the treatment of ...

The RedirecTT-1 trial showed a 78.9% response rate for talquetamab and teclistamab in relapsed multiple myeloma with extramedullary disease, significantly improving outcomes. INCA33989, a monoclonal ...

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organization that explores risks, knowledge sharing and best practices in the fight against infectious disease – has ...

Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy ...

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...